Simplex Trading
GANX icon

Simplex Trading’s Gain Therapeutics GANX Stock Holding History

Simplex Trading’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,200
Closed -$16.7K – 9440
2025
Q4 		$16.7K Buy
+5,200
New +$13.9K ﹤0.01% 6637
2023
Q3 		– Sell
-6,500
Closed -$29K – 9037
2023
Q2 		$29K Buy
6,500
+4,200
+183% +$20.5K ﹤0.01% 6386
2023
Q1 		$11K Buy
+2,300
New +$9.4K ﹤0.01% 7458

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Simplex Trading's GANX Position: Q1 2026 in Review

Simplex Trading reduced its Gain Therapeutics (GANX) stake by 72% in Q1 2026, selling an estimated $75.1K and leaving 13,439 shares worth $26.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6533.

Simplex Trading first reported a position in GANX in Q3 2022 and has held it in 9 quarters since. The position peaked at $154K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Simplex Trading held 13,439 shares of Gain Therapeutics worth $26.1K as of Q1 2026.
  • Simplex Trading sold 34,507 Gain Therapeutics shares in Q1 2026, an estimated $75.1K.
  • Gain Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #6533 holding.
  • Simplex Trading first reported a position in Gain Therapeutics in Q3 2022 and has held it in 9 quarters since.
  • Simplex Trading's Gain Therapeutics position peaked at $154K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.